Moody's Downgraded Rating On Roche Following Genentech Buyout
DNA Hot Sheet
Rating Summary:0 Buy, 0 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 20 | Down: 11 | New: 38
Moody's downgraded the long-term rating of Roche Holding AG to A2 from Aa1 following the company's successful tender offer for the remaining shares of Genentech, Inc. (NYSE: DNA). The outlook is stable.
Marie Fischer-Sabatie, a Vice President-Senior Analyst in Moody's Corporate Finance Group, said, "Moody's understands the strategic rationale behind the transaction, as Roche will obtain full access and control over Genentech's cash flows upon completion... However, the several positives gained from the transaction do not make up for the substantial weakening in Roche's credit metrics, as leverage will increase significantly."
Marie Fischer-Sabatie, a Vice President-Senior Analyst in Moody's Corporate Finance Group, said, "Moody's understands the strategic rationale behind the transaction, as Roche will obtain full access and control over Genentech's cash flows upon completion... However, the several positives gained from the transaction do not make up for the substantial weakening in Roche's credit metrics, as leverage will increase significantly."
You May Also Be Interested In
- UPDATE: Canaccord Genuity Downgrades The TJX Companies (TJX) to Hold; Growth is Slowing, Valuation is Stretched
- Auriga Reiterates a 'Buy' on DSW Inc. (DSW); Raising Estimates and PT After Great Q1
- Deutsche Bank Downgrades Nasdaq OMX Group Inc. (NDAQ) to Hold; Upgrading ICE on Lowered Expectations, Higher Volumes
Create E-mail Alert Related Categories
DowngradesSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
